Cost-effectiveness of financial incentives to improve glycemic control in adults with diabetes: A pilot randomized controlled trial

Leonard E Egede, Rebekah J Walker, Clara E Dismuke-Greer, Sarah Pyzyk, Aprill Z Dawson, Joni S Williams, Jennifer A Campbell, Leonard E Egede, Rebekah J Walker, Clara E Dismuke-Greer, Sarah Pyzyk, Aprill Z Dawson, Joni S Williams, Jennifer A Campbell

Abstract

Purpose: Determine the cost-effectiveness of three financial incentive structures in obtaining a 1% within group drop in HbA1c among adults with diabetes.

Methods: 60 African Americans with type 2 diabetes were randomized to one of three financial incentive structures and followed for 3-months. Group 1 (low frequency) received a single incentive for absolute HbA1c reduction, Group 2 (moderate frequency) received a two-part incentive for home testing of glucose and absolute HbA1c reduction and Group 3 (high frequency) received a multiple component incentive for home testing, attendance of weekly telephone education classes and absolute HbA1c reduction. The primary clinical outcome was HbA1c reduction within each arm at 3-months. Cost for each arm was calculated based on the cost of the intervention, cost of health care visits during the 3-month time frame, and cost of workdays missed from illness. Incremental cost effectiveness ratios (ICER) were calculated based on achieving a 1% within group drop in HbA1c and were bootstrapped with 1,000 replications.

Results: The ICER to decrease HbA1c by 1% was $1,100 for all three arms, however, bootstrapped standard errors differed with Group 1 having twice the variation around the ICER coefficient as Groups 2 and 3. ICERs were statistically significant for Groups 2 and 3 (p<0.001) indicating they are cost effective interventions.

Conclusions: Given ICERs of prior diabetes interventions range from $1,000-$4,000, a cost of $1,100 per 1% within group decrease in HbA1c is a promising intervention. Multi-component incentive structures seem to have the least variation in cost-effectiveness.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig 1. CONSORT flow diagram.
Fig 1. CONSORT flow diagram.

References

    1. Center for Disease Control and Prevention (CDC). National Diabetes Statistics Report, 2020. Atlanta, GA: Centers for Disease Control and Prevention, U.S. Dept of Health and Human Services; 2020.
    1. American Diabetes Association (ADA). Economic costs of diabetes in the US in 2017. Diabetes Care. 2018; 41: 917–928. 10.2337/dci18-0007
    1. Magliano DJ, Martin VJ, Owen AJ, Zomer E, Liew D. The productivity burden of diabetes at a population level. Diabetes Care. 2018; 41(5): 979–984. 10.2337/dc17-2138
    1. Dieleman JL, Baral R, Birger M, Bui AL, Bulchis A, Chapin A, et al.. US spending on personal health care and public health, 1996–2013. JAMA. 2016; 316(24): 2627–2646. 10.1001/jama.2016.16885
    1. Promberger M, Dolan P, Marteau TM. “Pay them if it works”: Discrete choice experiments on the acceptability of financial incentives to change health related behavior. Social Science & Medicine. 2012;75(12):2509–2514.
    1. Purnell JQ, Gernes R, Stein R, Sherraden MS, Knoblock-Hahn A. A systematic review of financial incentives for dietary behavior change. J Acad Nutr Diet. 2014;114(7):1023–1035. 10.1016/j.jand.2014.03.011
    1. Blondon K, Klasnja P, Coleman K, Pratt W. An exploration of attitudes toward the use of patient incentives to support diabetes self-management. Psychol Health. 2014;29(5):552–563. 10.1080/08870446.2013.867346
    1. DeFulio A, Silverman K. The use of incentives to reinforce medication adherence. Prev Med. 2012;55 Suppl(Suppl):S86–S94. 10.1016/j.ypmed.2012.04.017
    1. Mantzari E, Vogt F, Marteau TM. Financial incentives for increasing uptake of HPV vaccinations: a randomized controlled trial. Health Psychol. 2015;34(2):160–171. 10.1037/hea0000088
    1. Giles EL, Robalino S, McColl E, Sniehotta FF, Adams J. The effectiveness of financial incentives for health behaviour change: systematic review and meta-analysis. PLoS One, 2014;9(3) 1–7. Article e90347. 10.1371/journal.pone.0090347
    1. Chin J, Matson J, McCauley S, Anarella J, Gesten F, Roohan P. The impact of financial incentives on utilization and outcomes of diabetes prevention programs among Medicaid managed care adults in New York state. Contemporary Clinical Trials, 91, 1–6. 10.1016/j.cct.2020.105960
    1. Möllenkamp M, Zeppernick M, Schreyögg J. The effectiveness of nudges in improving the self-management of patients with chronic diseases: A systematic literature review. Health Policy. 2019;123(12):1199–1209. 10.1016/j.healthpol.2019.09.008
    1. Volpp KG, John LK, Troxel AB, Norton L, Fassbender J, Loewenstein G. A randomized controlled trial of financial incentives for weight loss. JAMA. 2008;300:2631–2637. 10.1001/jama.2008.804
    1. Elliott RA, Shinogle JA, Peele P, Bhosle M, Hughes DA. Understanding medication compliance and persistence from an economics perspective. Value Health. 2008;11:600–610. 10.1111/j.1524-4733.2007.00304.x
    1. Chapman GB, Brewer NT, Coups EJ, Brownlee S, Leventhal H, Leventhal EA. Value for the future and preventive health behavior. J Exp Psychol Appl. 2001;7:235–250.
    1. Mitchell MS, Goodman JM, Alter DM, et al.. Financial incentives for exercise adherence in adults: systematic review and meta-analysis. Am. J. Prev. Med., 2013;45(5):658–667. 10.1016/j.amepre.2013.06.017
    1. Sutherland K, Christianson JB, Leatherman S. Impact of targeted financial incentives on personal health behavior: a review of the literature. Med. Care Res. Rev., 2008;65(6 Suppl):36S–78S. 10.1177/1077558708324235
    1. Kane RL, Johnson PE, Town RJ, Butler M. A structured review of the effect of economic incentives on consumers’ preventive behavior. Am. J. Prev. Med. 2004;27(4):327–352. 10.1016/j.amepre.2004.07.002
    1. Breen RJ, Fergusion SG, Palmer MA. Higher incentive amounts do not appear to be associated with greater quit rates in financial incentive programmes for smoking cessation. Addictive Behaviors, 2020;110, 1–6.
    1. Fernandes R, Chinn CC, Li D, Halliday T, Frankland T, Ozaki RR. Impact of Financial Incentives on Health Outcomes and Costs of Care among Medicaid Beneficiaries with Diabetes in Hawai’i. Hawaii J Med Public Health. 2019;78(1):19–25.
    1. Judah G, Darzi A, Vlaev I, Gunn L, King D, King D, et al.. Incentives in diabetic eye assessment by screening (IDEAS) trial: a three-armed randomized controlled trial of financial incentives. Southampton (UK): NIHR Journals Library; March 2017.
    1. Siegel KR, Ali MK, Zhou X, Peng Ng B, Jawanda S, Proia K, et al.. Cost-effectiveness of Interventions to Manage Diabetes: Has the Evidence Changed Since 2008? Diabetes Care. 2020; 43(7):1557–1592. 10.2337/dci20-0017
    1. Lee Y, Mozaffarian D, Sy S, Huang Y, Liu J, Wilde PE, et al.. (2019) Cost-effectiveness of financial incentives for improving diet and health through Medicare and Medicaid: A microsimulation study. PLoS Med 16(3). 10.1371/journal.pmed.1002761
    1. Giles EL, Robalino S, Sniehotta FF, Adams J, McColl E. Acceptability of financial incentives for encouraging uptake of healthy behaviours: A critical review using systematic methods. Prev Med. 2015;73:145–158. 10.1016/j.ypmed.2014.12.029
    1. Pyne JM, Fortney JC, Tripathi SP, Maciejewski ML, Edlund MJ, Williams DK. Cost-effectiveness analysis of a rural telemedicine collaborative care intervention for depression. Arch Gen Psychiatry. 2010. August;67(8):812–21. 10.1001/archgenpsychiatry.2010.82
    1. US Department of Labor Inflation Calculator. Available at:
    1. MEPS 2015 Full Year Person-Level File. Available at:
    1. Giannini C, Mohn A, Chiarelli F. Technology and the issue of cost/benefit in diabetes. Diabetes Metab Res Rev. 2009;25 Suppl 1:S34–44. 10.1002/dmrr.986
    1. Wagner EH, Sandhu N, Newton KM, McCulloch DK, Ramsey SD, Grothaus LC. Effect of improved glycemic control on health care costs and utilization. JAMA. 2001; 285: 182–189. 10.1001/jama.285.2.182
    1. Li R, Zhang P, Barker LE, Chowdhury FM, Zhang X. Cost-effectiveness of interventions to prevent and control diabetes mellitus: a systematic review. Diabetes Care. 2010; 33:1872–1894. 10.2337/dc10-0843
    1. Egede LE, Walker RJ, Williams JS, Knapp R, Dismuke CE, Davidson T, et al.. Financial incentives and nurse coaching to enhance diabetes outcomes (FINANCE-DM): a trial protocol. BMJ Open 2020; 10:e043760. 10.1136/bmjopen-2020-043760

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj